Skip to content

US · MEDP · MEDICAL - DIAGNOSTICS & RESEARCH

Medpace Holdings, Inc. (MEDP) intrinsic value and stock valuation

$610.54as of 2026-11-21 · Mkt cap 16.41B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Medpace Holdings, Inc. DCF and intrinsic value

InvestorsCraft values MEDP with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from MEDP’s statements →

Medpace Holdings, Inc. Graham Number

Graham Number: $74.83d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Cincinnati, OH 45227 medpace.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$2.53B+22.3% 5y CAGRd
20132025
Net income
$451.1M+25.4% 5y CAGRd
20132025
Free cash flow
$681.9M+24.6% 5y CAGRd
20132025
Total equity
$459.1M-10.6% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$2.53B$2.11B$1.89B$1.46B$1.14B
Operating income$534.9M$446.9M$336.8M$278.7M$198.6M
Net income$451.1M$404.4M$282.8M$245.4M$181.9M
EPSd$15.3M$12.6M$8.88M$7.29M$4.82M
Operating cash flow$713.2M$608.8M$433.4M$388.1M$263.3M
Capital expenditure-$-31.36M-$-36.55M-$-36.65M-$-36.88M-$-28.27M
Free cash flow$681.9M$572.3M$396.7M$351.2M$235.1M
Total assets$1.98B$2.1B$1.66B$1.35B$1.66B
Total debt$250.5M$149.5M$142.1M$188.9M$131M
Net debt-$-246.55M-$-519.91M-$-103.33M$160.6M-$-330.34M
Total equity$459.1M$825.5M$559M$386.4M$952.9M
Cash and short-term investments$497.1M$669.4M$245.5M$28.3M$461.3M
Income statement
20252024202320222021
Revenue$2.53B$2.11B$1.89B$1.46B$1.14B
Cost of revenue$1.77B$1.45B$1.36B$1.03B$814.2M
Gross profit$760.6M$656.3M$524.5M$432.4M$328.2M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$197.6M$180.2M$161.4M$131.4M$108.4M
Other expenses$28.1M$29.3M$26.3M$22.3M$21.1M
Operating expenses$225.7M$209.4M$187.7M$153.7M$129.5M
Cost and expenses$2B$1.66B$1.55B$1.18B$943.8M
Interest income$0.00$25M$0.00$0.00$0.00
Interest expense$0.00$0.00$490K$2.9M$100K
Depreciation and amortization$28.1M$29.3M$26.3M$22.3M$21.1M
Ebitda$570.5M$505.2M$362.5M$308.1M$223.1M
Operating income$534.9M$446.9M$336.8M$278.7M$198.6M
Total other income/expenses, net$7.44M$29.1M-$-1.14M$4.16M$3.24M
Income before tax$542.4M$475.9M$335.7M$282.9M$201.9M
Income tax expense$91.3M$71.5M$52.9M$37.5M$20M
Net income$451.1M$404.4M$282.8M$245.4M$181.9M
Weighted average shares outstanding$28.9M$31M$30.7M$32.4M$35.9M
Weighted average diluted shares outstanding$29.5M$32M$31.8M$33.7M$37.7M
Balance sheet
20252024202320222021
Cash and short-term investments$497.1M$669.4M$245.5M$28.3M$461.3M
Net receivables$402.1M$296.4M$298.4M$253.4M$186.4M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$989.6M$1.03B$593.8M$334M$690.9M
Property, plant and equipment, net$248.9M$252.3M$265.4M$248.9M$222.7M
Goodwill and intangible assets$695.8M$696.8M$698.2M$700.4M$703.8M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$985.9M$1.07B$1.06B$1.02B$969M
Total assets$1.98B$2.1B$1.66B$1.35B$1.66B
Accounts payable$28.1M$32.5M$31.9M$33.1M$25.7M
Short-term debt$23.2M$23.3M$0.00$50M$0.00
Deferred revenue$854.4M$710.6M$559.9M$462.7M$344.6M
Total current liabilities$1.34B$1.1B$925.1M$803.5M$557.2M
Long-term debt$227.3M$126.2M$142.1M$138.9M$131M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$172.7M$170.8M$172.8M$162.6M$149.8M
Capital lease obligations$113.6M$126.2M$142.1M$138.9M$131M
Total liabilities$1.52B$1.28B$1.1B$966.1M$707M
Common stock$280K$310K$310K$310K$360K
Retained earnings-$-459.98M$8.17M-$-221.65M-$-359.83M$235M
Accumulated other comprehensive income (loss)-$-4.91M-$-14.74M-$-10.07M-$-12.39M-$-4.85M
Total equity$459.1M$825.5M$559M$386.4M$952.9M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$250.5M$149.5M$142.1M$188.9M$131M
Net debt-$-246.55M-$-519.91M-$-103.33M$160.6M-$-330.34M
Cash flow statement
20252024202320222021
Net income$451.1M$404.4M$282.8M$245.4M$181.9M
Depreciation and amortization$27.2M$29.3M$26.3M$22.3M$21.1M
Stock-based compensation$34.8M$25.5M$20.5M$21.4M$14.5M
Change in working capital$96.3M$157.2M$106.5M$106.1M$66.7M
Accounts receivable-$-106.22M$2.24M-$-48.28M-$-66.92M-$-24.98M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.63M-$-2.96M$1.05M$6.43M$1.87M
Net cash provided by operating activities$713.2M$608.8M$433.4M$388.1M$263.3M
Investments in property, plant and equipment-$-31.36M-$-36.55M-$-36.65M-$-36.88M-$-28.27M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-31.14M-$-28.31M-$-34.63M-$-38.74M-$-31.36M
Common stock issued$57M$0.00$0.00$0.00$0.00
Common stock repurchased-$-917.39M-$-169.87M-$-144.02M-$-847.85M-$-62.1M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-860.39M-$-154.01M-$-182.64M-$-775.77M-$-44.45M
Net change in cash-$-172.39M$424M$217.2M-$-433.04M$183.5M
Cash at end of period$497.1M$669.4M$245.5M$28.3M$461.3M
Operating cash flow$713.2M$608.8M$433.4M$388.1M$263.3M
Capital expenditure-$-31.36M-$-36.55M-$-36.65M-$-36.88M-$-28.27M
Free cash flow$681.9M$572.3M$396.7M$351.2M$235.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Medpace Holdings, Inc.

        Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

        CEO
        August James Troendle
        Employees
        6.2K
        Beta
        1.15

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Medpace Holdings, Inc. (MEDP)?

        Medpace Holdings, Inc. (MEDP) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MEDP undervalued?

        MEDP trades at a price of $610.54 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.